NL301304I2 - aprocitentan of een farmaceutisch aanvaardbaar zout daarvan - Google Patents

aprocitentan of een farmaceutisch aanvaardbaar zout daarvan

Info

Publication number: NL301304I2
Authority: NL; Netherlands
Prior art keywords: aprocitentan; pharmaceutically acceptable; acceptable salt; salt; pharmaceutically
Prior art date: 2007-08-17

Application number

NL301304C

Other languages

English (en)

Original Assignee

Idorsia Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-17

Filing date

2024-12-10

Publication date

2024-12-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40140023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301304(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2024-12-10 Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd

2024-12-19 Publication of NL301304I2 publication Critical patent/NL301304I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Physical Education & Sports Medicine (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)

NL301304C 2007-08-17 2024-12-10 aprocitentan of een farmaceutisch aanvaardbaar zout daarvan NL301304I2 (nl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IB2007053292		2007-08-17
IB2008052571		2008-06-26
PCT/IB2008/053282 WO2009024906A1 (en)	2007-08-17	2008-08-15	4-pyrimidinesulfamide derivative

Publications (1)

Publication Number	Publication Date
NL301304I2 true NL301304I2 (nl)	2024-12-19

Family

ID=40140023

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301304C NL301304I2 (nl)	2007-08-17	2024-12-10	aprocitentan of een farmaceutisch aanvaardbaar zout daarvan

Country Status (31)

Country	Link
US (1)	US8324232B2 (nl)
EP (1)	EP2190837B1 (nl)
JP (1)	JP5323075B2 (nl)
KR (1)	KR101528946B1 (nl)
CN (1)	CN101772494B (nl)
AR (1)	AR070018A1 (nl)
AU (1)	AU2008290234B2 (nl)
BR (1)	BRPI0815360B8 (nl)
CA (1)	CA2695511C (nl)
CY (1)	CY1113255T1 (nl)
DK (1)	DK2190837T3 (nl)
ES (1)	ES2394584T3 (nl)
FI (1)	FIC20240041I1 (nl)
FR (1)	FR24C1047I2 (nl)
HR (1)	HRP20120878T1 (nl)
HU (1)	HUS2400041I1 (nl)
IL (1)	IL203936A (nl)
LT (1)	LTPA2024534I1 (nl)
MA (1)	MA31702B1 (nl)
MX (1)	MX2010001837A (nl)
MY (1)	MY152281A (nl)
NL (1)	NL301304I2 (nl)
NO (1)	NO2024053I1 (nl)
NZ (1)	NZ583990A (nl)
PL (1)	PL2190837T3 (nl)
PT (1)	PT2190837E (nl)
RU (1)	RU2485116C2 (nl)
SI (1)	SI2190837T1 (nl)
TW (1)	TWI411437B (nl)
WO (1)	WO2009024906A1 (nl)
ZA (1)	ZA201001872B (nl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2907811A1 (en)	2014-02-14	2015-08-19	Actelion Pharmaceuticals Ltd.	Process for manufacturing pyrimidine sulfamide derivatives
US10669264B2 (en) *	2015-11-30	2020-06-02	Laurus Labs Limited	Process for the preparation of macitentan
WO2017191565A1 (en) *	2016-05-04	2017-11-09	Shilpa Medicare Limited	Process for preparation of macitentan
ES3038007T3 (en)	2017-02-27	2025-10-08	Idorsia Pharmaceuticals Ltd	Combinations of aprocitentan with further active ingredients for the treatment of resistant hypertension
BR112020010831A2 (pt) *	2017-11-30	2020-11-10	Idorsia Pharmaceuticals Ltd	composição farmacêutica, aprocitentan, e, método
CN108997223B (zh) *	2018-08-09	2020-06-30	浙江先锋科技股份有限公司	5-(4-溴苯基)-4，6-二氯嘧啶的制备方法
SMT202400274T1 (it)	2018-12-21	2024-09-16	Actelion Pharmaceuticals Ltd	Macitentan per il trattamento di ipertensione arteriosa polmonare
TW202042818A (zh)	2019-01-25	2020-12-01	瑞士商艾克泰聯製藥有限公司	用於治療慢性血栓性肺高血壓之醫藥組成物
AU2020378025A1 (en) *	2019-11-07	2022-06-23	Crystal Pharmaceutical (Suzhou) Co., Ltd.	Crystal form of Aprocitentan, preparation method therefor and use thereof
EP4153574A1 (en)	2020-05-21	2023-03-29	Teva Pharmaceuticals International GmbH	Solid state forms of aprocitentan and process for preparation thereof
CN114644595A (zh) *	2020-12-19	2022-06-21	普济生物科技（台州）有限公司	阿普昔腾坦的无定型态、其药物组合物和用途
WO2023111797A1 (en) *	2021-12-17	2023-06-22	Janssen Biotech, Inc.	Pyrimidine sulfamide derivatives and process for manufacturing them
KR20250016196A (ko)	2022-05-22	2025-02-03	이도르시아 파마슈티컬스 리미티드	고혈압의 치료를 위한 아프로시텐탄
KR20250019676A (ko)	2022-05-25	2025-02-10	이도르시아 파마슈티컬스 리미티드	소듐 (5-(4-브로모페닐)-6-(2-((5-브로모피리미딘-2-일)옥시)에톡시)피리미딘-4-일)(술파모일)아미드의 결정질 형태
CN119330888B (zh) *	2024-10-25	2025-11-28	上海药坦药物研究开发有限公司	一种阿普昔腾坦的制备方法
CN119528820B (zh) *	2024-11-29	2025-10-10	浙江国邦药业有限公司	一种阿普昔腾坦的合成方法
CN119528821B (zh) *	2024-11-29	2025-10-10	浙江国邦药业有限公司	一种阿普昔腾坦的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2801584A1 (de)	1978-01-14	1979-07-19	Bayer Ag	Halogensubstituierte pyrimidin (2)yl-thiono-thiol-phosphor(phosphon)- saeureester, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide
JPH04103525A (ja)	1990-08-22	1992-04-06	Sanwa Kagaku Kenkyusho Co Ltd	難水溶性薬物の持続性製剤化方法
RU2086544C1 (ru)	1991-06-13	1997-08-10	Хоффманн-Ля Рош АГ	Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW394761B (en)	1993-06-28	2000-06-21	Hoffmann La Roche	Novel Sulfonylamino Pyrimidines
US5523204A (en)	1993-12-10	1996-06-04	Becton Dickinson And Company	Detection of nucleic acids in cells by strand displacement amplification
WO1996016963A1 (de)	1994-11-25	1996-06-06	F. Hoffmann-La Roche Ag	Sulfonamide und deren verwendung als heilmittel
TW313568B (nl)	1994-12-20	1997-08-21	Hoffmann La Roche
US5739333A (en)	1995-05-16	1998-04-14	Tanabe Seiyaku Co., Ltd.	Sulfonamide derivative and process for preparing the same
TW442301B (en)	1995-06-07	2001-06-23	Sanofi Synthelabo	Pharmaceutical compositions containing irbesartan
TW414792B (en)	1995-12-20	2000-12-11	Yamanouchi Pharma Co Ltd	An arylethensulfonamide derivative having endothelin receptor antagonistic effect and its pharmaceutical composition
US20010014352A1 (en)	1998-05-27	2001-08-16	Udit Batra	Compressed tablet formulation
TWI284642B (en)	1999-01-18	2007-08-01	Hoffmann La Roche	Novel heterocyclic sulfonamides
NZ512526A (en)	1999-09-03	2004-01-30	Actelion Pharmaceuticals Ltd	4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin.
AU3536701A (en)	1999-12-22	2001-07-03	Actelion Pharmaceuticals Ltd	Butyne diol derivatives
US20040062803A1 (en)	1999-12-22	2004-04-01	Hedden David B.	Sustained-release formulation of a cyclooxygenase-2 inhibitor
MXPA02006461A (es)	1999-12-31	2003-09-05	Texas Biotechnology Corp	Sulfonamidas y derivados de las mismas que modulan la actividad de endotelina.
AU2001263850A1 (en)	2000-04-20	2001-11-07	Actelion Pharmaceuticals Ltd	Pyrimidine-sulfonamides having endothelin-antagonist activity
WO2001081338A1 (en)	2000-04-25	2001-11-01	Actelion Pharmaceuticals Ltd	Substituted sulfonylaminopyrimidines
JP2001335469A (ja)	2000-05-26	2001-12-04	Lion Corp	固体製剤の製造方法
HUP0301802A3 (en)	2000-06-28	2009-04-28	Teva Pharma	Process for producing carvedilol, crystalline carvedilol, process for producing it and pharmaceutical composition containing it
CN1486302A (zh)	2000-12-07	2004-03-31	CV��ƹ�˾	作为抗冠状动脉疾病或动脉硬化的abca-1加强化合物的取代1,3,5-三嗪和嘧啶
ATE323079T1 (de) *	2000-12-18	2006-04-15	Actelion Pharmaceuticals Ltd	Neue sulfamiden und deren verwendung als endothelin-antagonisten
FR2819720B1 (fr)	2001-01-22	2004-03-12	Fournier Lab Sa	Nouveaux comprimes de fenofibrate
KR20030041577A (ko)	2001-11-20	2003-05-27	디디에스텍주식회사	난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
PL208114B1 (pl)	2002-02-26	2011-03-31	Astrazeneca Ab	Kompozycja farmaceutyczna, sposób jej wytwarzania i zastosowanie
RU2329255C2 (ru) *	2002-12-02	2008-07-20	Актелион Фармасьютиклз Лтд	Пиримидинсульфамиды и их использование в качестве антагонистов эндотелиальных рецепторов
HRP20050675A2 (en)	2003-02-25	2005-10-31	Eli Lilly And Company	Crystalline non-solavated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
EP2292209A3 (en) *	2005-09-12	2011-05-04	Actelion Pharmaceuticals Ltd.	Stable pharmaceutical composition comprising a pyramidine-sulfamide
AR062501A1 (es)	2006-08-29	2008-11-12	Actelion Pharmaceuticals Ltd	Composiciones terapeuticas
PT2254570E (pt)	2008-02-20	2014-02-17	Actelion Pharmaceuticals Ltd	Combinação que compreende paclitaxel para o tratamento de cancro de ovário
KR101678699B1 (ko)	2008-08-13	2016-11-23	액테리온 파마슈티칼 리미티드	마시텐탄을 포함하는 치료 조성물

2008
- 2008-02-07 MX MX2010001837A patent/MX2010001837A/es active IP Right Grant
- 2008-08-14 AR ARP080103552A patent/AR070018A1/es not_active Application Discontinuation
- 2008-08-15 ES ES08807330T patent/ES2394584T3/es active Active
- 2008-08-15 AU AU2008290234A patent/AU2008290234B2/en active Active
- 2008-08-15 WO PCT/IB2008/053282 patent/WO2009024906A1/en not_active Ceased
- 2008-08-15 BR BRPI0815360A patent/BRPI0815360B8/pt active IP Right Grant
- 2008-08-15 JP JP2010520674A patent/JP5323075B2/ja active Active
- 2008-08-15 KR KR1020107004945A patent/KR101528946B1/ko active Active
- 2008-08-15 TW TW097131323A patent/TWI411437B/zh active
- 2008-08-15 CN CN2008801016796A patent/CN101772494B/zh active Active
- 2008-08-15 CA CA2695511A patent/CA2695511C/en active Active
- 2008-08-15 US US12/673,413 patent/US8324232B2/en active Active
- 2008-08-15 MY MYPI20100680 patent/MY152281A/en unknown
- 2008-08-15 PL PL08807330T patent/PL2190837T3/pl unknown
- 2008-08-15 EP EP08807330A patent/EP2190837B1/en active Active
- 2008-08-15 SI SI200830785T patent/SI2190837T1/sl unknown
- 2008-08-15 PT PT08807330T patent/PT2190837E/pt unknown
- 2008-08-15 DK DK08807330.9T patent/DK2190837T3/da active
- 2008-08-15 NZ NZ583990A patent/NZ583990A/en unknown
- 2008-08-15 HR HRP20120878AT patent/HRP20120878T1/hr unknown
- 2008-08-15 RU RU2010109543/04A patent/RU2485116C2/ru active
2010
- 2010-02-14 IL IL203936A patent/IL203936A/en active IP Right Grant
- 2010-03-12 MA MA32692A patent/MA31702B1/fr unknown
- 2010-03-16 ZA ZA2010/01872A patent/ZA201001872B/en unknown
2012
- 2012-10-25 CY CY20121101015T patent/CY1113255T1/el unknown
2024
- 2024-11-27 HU HUS2400041C patent/HUS2400041I1/hu unknown
- 2024-12-02 FI FIC20240041C patent/FIC20240041I1/fi unknown
- 2024-12-03 NO NO2024053C patent/NO2024053I1/no unknown
- 2024-12-04 LT LTPA2024534C patent/LTPA2024534I1/lt unknown
- 2024-12-05 FR FR24C1047C patent/FR24C1047I2/fr active Active
- 2024-12-10 NL NL301304C patent/NL301304I2/nl unknown

Also Published As

Publication number	Publication date
JP5323075B2 (ja)	2013-10-23
FIC20240041I1 (fi)	2024-12-02
IL203936A (en)	2016-03-31
EP2190837B1 (en)	2012-08-15
PT2190837E (pt)	2012-10-31
EP2190837A1 (en)	2010-06-02
HRP20120878T1 (hr)	2012-11-30
CN101772494A (zh)	2010-07-07
BRPI0815360A8 (pt)	2017-12-26
AU2008290234A1 (en)	2009-02-26
RU2485116C2 (ru)	2013-06-20
CY1113255T1 (el)	2016-04-13
MA31702B1 (fr)	2010-09-01
MX2010001837A (es)	2010-03-10
US8324232B2 (en)	2012-12-04
KR101528946B1 (ko)	2015-06-15
TWI411437B (zh)	2013-10-11
NZ583990A (en)	2012-06-29
AU2008290234B2 (en)	2013-11-21
HUS2400041I1 (hu)	2024-12-28
WO2009024906A1 (en)	2009-02-26
RU2010109543A (ru)	2011-09-27
AR070018A1 (es)	2010-03-10
BRPI0815360A2 (pt)	2015-02-10
TW200927122A (en)	2009-07-01
FR24C1047I2 (fr)	2025-10-10
ZA201001872B (en)	2011-05-25
BRPI0815360B8 (pt)	2021-05-25
DK2190837T3 (da)	2012-10-08
PL2190837T3 (pl)	2013-01-31
US20120142716A1 (en)	2012-06-07
SI2190837T1 (sl)	2012-11-30
HK1144196A1 (en)	2011-02-02
KR20100052517A (ko)	2010-05-19
JP2010536742A (ja)	2010-12-02
NO2024053I1 (no)	2024-12-03
ES2394584T3 (es)	2013-02-04
CN101772494B (zh)	2013-05-15
CA2695511A1 (en)	2009-02-26
FR24C1047I1 (fr)	2025-01-10
BRPI0815360B1 (pt)	2018-12-04
LTPA2024534I1 (nl)	2024-12-27
CA2695511C (en)	2015-11-03
MY152281A (en)	2014-09-15

Publication	Publication Date	Title
NL301305I2 (nl)	2024-12-30	Vibegron of een farmaceutisch aanvaardbaar zout daarvan
NL301209I2 (nl)	2023-01-24	capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL301166I2 (nl)	2022-07-06	Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301256I2 (nl)	2024-01-11	cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan
NL301071I2 (nl)	2020-12-01	alpelisib of een farmaceutisch aanvaardbaar zout ervan
NL301304I2 (nl)	2024-12-19	aprocitentan of een farmaceutisch aanvaardbaar zout daarvan
NL301291I2 (nl)	2024-10-30	sparsentan of een farmaceutisch aanvaardbaar zout daarvan
NL301003I2 (nl)	2019-10-29	Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan
NL300993I2 (nl)	2019-07-11	Apalutamide of een farmaceutisch aanvaardbaar zout daarvan
NL301187I2 (nl)	2022-08-04	Rimegepant of een farmaceutisch aanvaardbaar zout daarvan
NL301250I2 (nl)	2023-11-23	piflufolastat (18F) of een farmaceutisch aanvaardbaar zout daarvan
NL301106I2 (nl)	2021-08-03	Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NL301035I2 (nl)	2020-04-15	upadacitinib of een farmaceutisch aanvaardbaar zout daarvan
NL301284I2 (nl)	2024-09-04	Etrasimod, of een farmaceutisch aanvaardbaar zout daarvan, zoals etrasimod arginine
NL301248I2 (nl)	2023-11-20	atogepant of een farmaceutisch aanvaardbaar zout daarvan
NL301157I2 (nl)	2023-11-09	odevixibat of een farmaceutisch aanvaardbaar zout daarvan
NL301299I2 (nl)	2024-12-11	Capivasertib, eventueel in de vorm van een farmaceutisch aanvaardbaar zout
NL301318I2 (nl)	2025-03-13	Erdafitinib of een farmaceutisch aanvaardbaar zout daarvan of een solvaat daarvan
NL300886I2 (nl)	2017-10-24	baricitinib, of een farmaceutisch aanvaardbaar zout daarvan
NL301096I2 (nl)	2021-04-12	Filgotinib of een zout daarvan
NL301065I2 (nl)	2020-10-28	Ozanimod of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder ozanimodhydrochloride
NL301202I1 (nl)	2022-11-09	Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline
NO2019024I1 (no)	2019-05-20	Brigatinib eller et farmasøytisk akseptabelt salt derav
NL300901I2 (nl)	2017-11-16	pibrentasvir of een farmaceutisch aanvaardbaar zout daarvan
NO2017059I1 (no)	2017-11-13	ribosiklib eller et farmasøytisk akseptabelt salt derav